590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel 177Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

Oncology: Clinical Therapy and Diagnosis -> Clinical Therapy -> Prostate/GU 590

590 - Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel ¹⁷⁷Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen (ID 773)

Session Name

Prostate: PSMA radioligand therapy

Speakers

Y. Seo

Authors

Presentation Topic

Oncology: Clinical Therapy and Diagnosis -> Clinical Therapy -> Prostate/GU

Presentation Number

590

Previous Eposter

588 - ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer (ID 771)

Next Eposters

591 - Early prostate-specific antigen changes and clinical outcome following ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer (ID 775)

593 - Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study (ID 777)

594 - Hematotoxicity after Radioligand Therapy with ¹⁷⁷Lu-PSMA-617 in Patients with Metastastic Prostate Cancer (ID 776)

595 - PSMA-ligand uptake in posttherapeutic ¹⁷⁷Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC (ID 778)

598 - Bridging brain structural/functional connectivity and tau load in PSP: A [18F]PI-2620 PET/MRI study (ID 855)

600 - Interaction of Striatal Dopaminergic and Cholinergic Activity in Parkinson Disease: A Multimodal Imaging Study Based on ¹¹C-DTBZ and ¹⁸F- FEOBV PET Combined with Diffusion Tensor Imaging (ID 856)

602 - Assessment of α4β2 nicotinic acetylcholine receptor (nAChR) availability and neuronal response to rewarding food-cues in human obesity using simultaneous PET-MRI (ID 857)

605 - The F18 FDG PET in breast carcinoma: Do patient characteristics, tumor histology or receptor status, have any impact on final staging? (ID 1040)

606 - Impact of a Gaussian filter applied to post-reconstruction PET images on radiomic features to predict complete pathological response in breast cancer (ID 1041)

608 - Visceral fat metabolic activity evaluated by preoperative ¹⁸F-FDG PET/CT is independently associated with axillary lymph node metastasis in postmenopausal luminal breast cancer (ID 1043)